BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34767564)

  • 1. Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
    Rivolo S; Di Fusco M; Polanco C; Kang A; Dhanda D; Savone M; Skandamis A; Kongnakorn T; Soto J
    PLoS One; 2021; 16(11):e0259251. PubMed ID: 34767564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
    Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective.
    Ademi Z; Pasupathi K; Liew D
    Appl Health Econ Health Policy; 2017 Jun; 15(3):363-374. PubMed ID: 27699648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Hijazi Z; Alexander JH; Li Z; Wojdyla DM; Mehran R; Granger CB; Parkhomenko A; Bahit MC; Windecker S; Aronson R; Berwanger O; Halvorsen S; de Waha-Thiele S; Sinnaeve P; Darius H; Storey RF; Lopes RD
    Circulation; 2021 Mar; 143(12):1215-1223. PubMed ID: 33461308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
    Dorian P; Kongnakorn T; Phatak H; Rublee DA; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Lip GY
    Eur Heart J; 2014 Jul; 35(28):1897-906. PubMed ID: 24513791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium.
    Kongnakorn T; Lanitis T; Lieven A; Thijs V; Marbaix S
    Clin Drug Investig; 2014 Oct; 34(10):709-21. PubMed ID: 25164005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
    Bahit MC; Vora AN; Li Z; Wojdyla DM; Thomas L; Goodman SG; Aronson R; Jordan JD; Kolls BJ; Dombrowski KE; Vinereanu D; Halvorsen S; Berwanger O; Windecker S; Mehran R; Granger CB; Alexander JH; Lopes RD
    JAMA Cardiol; 2022 Jul; 7(7):682-689. PubMed ID: 35612866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain].
    Escolar-Albaladejo G; Barón-Esquivias G; Zamorano JL; Betegón-Nicolás L; Canal-Fontcuberta C; de Salas-Cansado M; Rubio-Rodríguez D; Rubio-Terrés C
    Aten Primaria; 2016; 48(6):394-405. PubMed ID: 26832316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
    Lopes RD; Heizer G; Aronson R; Vora AN; Massaro T; Mehran R; Goodman SG; Windecker S; Darius H; Li J; Averkov O; Bahit MC; Berwanger O; Budaj A; Hijazi Z; Parkhomenko A; Sinnaeve P; Storey RF; Thiele H; Vinereanu D; Granger CB; Alexander JH;
    N Engl J Med; 2019 Apr; 380(16):1509-1524. PubMed ID: 30883055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
    Lanitis T; Kongnakorn T; Jacobson L; De Geer A
    Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
    de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
    Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.
    Harskamp RE; Fanaroff AC; Lopes RD; Wojdyla DM; Goodman SG; Thomas LE; Aronson R; Windecker S; Mehran R; Granger CB; Alexander JH
    J Am Coll Cardiol; 2022 Feb; 79(5):417-427. PubMed ID: 35115097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of antithrombotic agents for atrial fibrillation in older adults at risk for falls: a mathematical modelling study.
    Wong EKC; Belza C; Naimark DMJ; Straus SE; Wijeysundera HC
    CMAJ Open; 2020; 8(4):E706-E714. PubMed ID: 33158928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.
    Stevanović J; Pompen M; Le HH; Rozenbaum MH; Tieleman RG; Postma MJ
    PLoS One; 2014; 9(8):e103974. PubMed ID: 25093723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
    Welsh RC; Dehghani P; Lopes R; Wojdyla DM; Aronson R; Granger CB; Windecker S; Vora AN; Vinereanu D; Halvorsen S; Parkhomenko A; Mehran R; Alexander JH; Goodman S
    Open Heart; 2022 Feb; 9(1):. PubMed ID: 35172988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.